Alternative therapies in patients with non-muscle invasive bladder cancer

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Bladder cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Despite, the majority of the cases were diagnosed as non-muscle invasive bladder cancer (NMIBC) with favorable prognosis, it has tendency to recur or progress to a higher grade or stage. The first line treatment of patients with NMIBC is transurethral resection with adjuvant therapies primarily intravesical Bacillus Calmette-Guérin (BCG) immunotherapy. However, in a portion of patients whose BCG treatment failed, alternative treatments may be required. Furthermore, intravesical BCG may be contraindicated in or untolerated by a group of patients. For these patients, some treatment options are readily available and a variety of them are currently under clinical investigation. In this review, these alternative therapies have been summarized.

Original languageEnglish (US)
Pages (from-to)414-424
Number of pages11
JournalTurkish Journal of Urology
Issue number4
StatePublished - Dec 2017


  • BCG
  • Bladder cancer
  • Instillation
  • Survival

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Alternative therapies in patients with non-muscle invasive bladder cancer'. Together they form a unique fingerprint.

Cite this